logo
London mansion sales collapse as non-doms flee Britain

London mansion sales collapse as non-doms flee Britain

Telegraph19-06-2025
Mansion sales in London have slumped as the Chancellor's tax raid dents the capital's appeal to wealthy buyers.
Transactions involving London homes worth more than $10m (£7.5m) plummeted by 37pc year-on-year in the first three months of 2025, according to Knight Frank. The value of deals also dropped by 30pc to £592m.
Separate data from LonRes showed a 15pc drop in sales of properties worth £5m or more. However, there was a 22pc leap in these homes being put on the market.
Knight Frank blamed the slump on London's 'adverse taxation shifts'. It comes after Rachel Reeves scrapped non-dom status and began charging 40pc inheritance tax on global assets. Taxes on private schools fees have also increased.
The changes have prompted many wealthy people to move out of Britain to escape the charges. Ms Reeves is now considering reversing her inheritance tax changes in an effort to stem the exodus.
Liam Bailey, of Knight Frank, said: 'London has definitely been hit by much greater uncertainty around wealth taxation. The super-prime market hasn't stopped, but it is a lot tougher than it was.'
He said non-doms were 'not the majority of buyers in this market segment', but there 'has been a degree of contagion through weaker sentiment'.
Mr Bailey said: 'The key issue for the market is that the UK is just lacking a coherent narrative around where it wants to go in terms of attracting very mobile global wealth.
'London has massive strengths and attractions for this group – but if it is thought that it is good to have wealthy people in your country, it looks like we need a stronger plan from the Government to attract them. The competition from Italy, Dubai, the US and beyond is getting tougher.'
Sales of properties worth $10m or more rose by 5.7pc in Dubai over the first three months of the year according to Knight Frank. The estate agency said its 'low tax environment continues to draw global capital'. Other global hotspots include New York and Palm Beach in south Florida.
A lack of buyers in London is forcing wealthy sellers to offer steep discounts. LonRes said there were 45pc more discounts to mansion asking prices than there were last year.
Magda Wierzycka, the millionaire founder of UK venture capital fund Braavos, described her struggle to offload a property in Kensington to The Telegraph on Wednesday. She said: 'I put my flat in Kensington on the market five months ago, but because so many like me are leaving there are hardly any buyers.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Thousands await GCSE results across Northern Ireland
Thousands await GCSE results across Northern Ireland

The Independent

timean hour ago

  • The Independent

Thousands await GCSE results across Northern Ireland

Thousands of young people across Northern Ireland are set to receive their GCSE results today. Scores of students will also receive vocational qualification results. Last year around a third of the 32,018 students in the region who received GCSEs results achieved a grade A or better. Last Thursday, more than 25,000 students across the region received their AS and A-level examination results, with 30.4% of entries having achieved the top A* to A grades. Northern Ireland continued to outperform other parts of the UK in the A-level results last week with nearly 86% of pupils in the region receiving an A* to C grade, while the figures for England and Wales were just under 78%. Stormont Economy Minister Caoimhe Archibald has urged students receiving results today and their parents/carers to make use of the advice and guidance offered by her department's Careers Service. 'Making informed decisions following your exam results is crucial in helping you consider the next step on your journey,' she said. 'No matter what your results were, there are many opportunities available to you and I would urge you to examine these fully. 'You may wish to remain at school, or you might want to explore further education courses, start an apprenticeship or training programme or go into employment – my department's Careers Service can provide you with all the help and guidance you need. 'Whatever choice you make, I want to pass on my very best wishes for the future.' Young people and parents can find useful information on the Careers Service website at

Is this a good time to buy shares in Convatec?
Is this a good time to buy shares in Convatec?

Times

time2 hours ago

  • Times

Is this a good time to buy shares in Convatec?

After a volatile year for shares in Convatec they received a welcome boost on Wednesday when the FTSE 100 medical equipment company launched a share buyback of up to $300 million. The programme, representing up to 5 per cent of Convatec's market capitalisation, will run until the end of the year. The return of surplus capital to shareholders lifted the shares 5.6 per cent, gaining 13p, to close at 244¼p on the London Stock Exchange, the session's biggest riser on the premier share index. The buyback, being handled by UBS, was received by the market as a sign of health in the outlook for Convatec, whose shares, which were up 30 per cent in the first half of the year, have de-rated since June on concerns about product reimbursement cuts in the United States, its largest market, where the Trump administration has launched an efficiency drive. Despite the stock having seemingly priced in the exposure, some investors have remained on the sidelines, concerned that changes to US federal reimbursement in chronic care and skin substitutes could hit Convatec's sales and forecasts more than expected. Convatec has quantified the potential impact. It guided at its half-year results at the end of July for a potential 1 per cent to 2 per cent headwind on its 2026 revenues and the same range in 2027. The company also reiterated its forecasts for the current financial year, of group organic revenue growth of between 5.5 per cent and 7 per cent. This excludes sales of at least $75 million from InnovaMatrix, a wound treatment whose sales are uncertain because of the prospect of a curtailment of Medicare coverage, a US health insurance scheme. Convatec also reiterated an adjusted operating margin between 22 per cent and 22.5 per cent for this year and said it remained on course to 'consistently deliver' medium-term targets of 5 per cent to 7 per cent organic revenue growth and to reach a 'mid-20s' percentage adjusted operating margin by 2026 or 2027. Sellside bulls argue that investors have overlooked Convatec's results. Uncertainty, though, increased this month when Convatec announced, in a brief statement, that Karim Bitar, its well-regarded chief executive, was taking an indefinite medical leave of absence from the company. He has been replaced by Jonny Mason, the chief financial officer, on an interim basis, and Fiona Ryder, the group financial controller, will in turn take Mason's place as chief financial officer in the interim. Since Bitar, 60, was parachuted in as chief executive by Novo Holdings, a top shareholder, in 2019, he has led the turnaround of the FTSE 100 company after a period of profit warnings and boardroom upheaval. Convatec, founded in 1978, employs about 10,000 people globally and operates in around 90 countries. The company's strategy centres on four chronic care categories — including ostomy and continence care — and prioritises 12 key markets, with the United States as its largest. Since 2019 revenue growth has risen from 2.3 per cent; Convatec has delivered six straight years of accelerating growth; its annual research and development expenditure has doubled to about $100 million; and it has replenished its pipeline of new products. Amid the US and leadership uncertainty, then, the share buyback has helped reinforce the bull case. The buyback was consistent with Convatec's capital allocation plans, under which it targets a 2 times net debt/ebitda leverage ratio. Analysts at UBS, Convatec's house broker, forecast a year-end ratio of 1.3 times, rising to 1.7 times following the buyback. The broker, which reiterated its 'buy' rating and 231p price target, believes Convatec has the cashflows for a consistent buyback programme, which excluding mergers and acquisitions, could return up to $2 billion, or one third of Convatec's existing market capitalisation over the next four years. Similarly, Berenberg told clients on Wednesday, before the buyback was announced, that the 20 per cent de-rating in Convatect's shares since June was a 'buying opportunity', with the company trading on a 16 times price-earnings ratio. Advice Buy Why Buyback underpins confident outlook and shares have de-rated since Tempus's recommendation in February

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store